Dr. Surendra Rajpurohit
Dr. Rajpurohit Lab is working on the Experimental Therapeutic in Glioblastoma and Cardio-oncology by using in-vivo transparent transgenic zebrafish and mouse model which includes high throughput (HT) drug discovery, repurposing of FDA approved drugs, identification of novel hit and lead drugs, drug validation and drug toxicity in glioblastoma and cardio oncology therapeutics.
Dr. Rajpurohit Lab developing and establishing in-vivo transparent transgenic cellular phenotype model of zebrafish to study of the cell death process (Annexin5 and Inflammatory activity NFkB in the microglia-resident macrophage of the brain and cardiac myocytes. In cardio-oncology, our research is on the development of a transparent transgenic zebrafish model to study Annexin-5 and NF-kB activity in normal and inflamed cardiac myocytes. In glioblastoma research, his lab determines the role of NFkB and microglia function under normal healthy status and in glioblastomas by using mouse and zebrafish model. He is establishing the role of annexin-5 and NF-kB activity in the cardiovascular function under normal and in metabolic aberration by developing homozygous casper/ myl7:RFP; annexin-5:YFP/NF-kB:GFP transgenic zebrafish.
Dr. Rajpurohit designed and established the novel whole organism based ARQiv (automated reporter based quantitative in-vivo HT-screen) platform. This novel devise facilitates large-scale HT drug or chemical screen to find the hit and lead drug for targeted disease module. He has successfully applied this unique platform to screen over 3200 drug candidates to identify novel pathway for increasing pancreatic beta-cell neogenesis and proliferation.
Dr Rajpurohit Lab is working on various novel research projects of K21 Experimental Therapeutics by using the Zebrafish model system. Evaluation of the Role of K21 Drug in Health Preservation and Disease Prevention by Using Zebrafish Model. Optimization of K21 Dose and Dynamic Treatment Regime (DTR) for in-vivo zebrafish experimental therapeutics. K21 Accelerates Development & Growth in Zebrafish including Bone micro–CT Profile. Study of K21 Efficacy on Brine-shrimp Hatching as Healthy Primary Host Food Supply Chain. The State-of-The-Art Zebrafish Modeling System for K21 Experimental Therapeutics. The Use of a Newly Developed Transparent Transgenic Zebrafish to Study the Anti-inflammatory and Anti-Cancer Properties of K21. Repurposing of K21 for Cardio-oncology Therapeutics to Prevent Drug-Induced Cardiovascular Toxicity. K21 Associated Zebrafish Comparative Genomics.